Bispecific antibodies have high response rates in relapsed/refractory myeloma compared to other myeloma therapies. However, this doesn't mean that all patients will respond to bispecific antibody therapy.

It could be possible that you don't ever have a response to bispecific therapy or that shortly after seeing a response, that response diminishes. This would mean you are refractory to the bispecific antibody therapy that you were prescribed.

However, this doesn't mean that all bispecific antibody therapy is off the table. It could be that you are experiencing T-cell exhaustion, that your myeloma cells have "shed" their BCMA protein target, or a number of other reasons why the treatment did not work at this time.

Have an honest conversation with your doctor about the next steps so you can find another therapy that works well for you. Fortunately, multiple myeloma research is abundant, and there are many approved therapies and clinical trials that could provide the best treatment pathway for you.